Stockscreener 앱 받기
68.59
2.49%
-1.75
시간 외 거래:
68.59
Incyte Corp 주식(INCY)의 최신 뉴스
Anal Cancer Market Research Report 2025-2035 with Competitive Profiles of Incyte, BioMimetix, Bristol Myers Squibb, and AstraZeneca - Yahoo Finance
Incyte’s Q2 2025 Earnings: What to Expect - inkl
Incyte to Report Second Quarter Financial Results - Yahoo Finance
William Blair Maintains ‘Hold’ Rating on Incyte Corporation (INCY), Citing Future Revenue Uncertainties - Insider Monkey
Incyte Announces Equity Awards for New CEO Bill Meury with Performance-Based Incentives - MyChesCo
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock? - MSN
Incyte: New CEO Brings A New Possible Outcome (NASDAQ:INCY) - Seeking Alpha
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Meury named Incyte CEO as Hoppenot departs - Delaware Business Times
Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran” - Yahoo Finance
Citi reiterates buy rating on Incyte stock amid CEO transition - Investing.com
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - MSN
How Is Incyte’s Stock Performance Compared To Other Biotech Stocks? - Barchart.com
Incyte stock falls after FDA extends review of pediatric eczema cream - Investing.com
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis - Business Wire
Incyte (INCY) Secures FDA Approval for Monjuvi in Follicular Lym - GuruFocus
Incyte wins FDA label expansion for lymphoma drug Monjuvi (INCY) - Seeking Alpha
FDA Approves Incyte's Monjuvi for Follicular Lymphoma Treatment | INCY Stock News - GuruFocus
FDA approves Monjuvi combination therapy for follicular lymphoma By Investing.com - Investing.com Canada
FDA Approves Incyte's (INCY) Tafasitamab-Cxix for Follicular Lym - GuruFocus
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in - GuruFocus
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma - Business Wire
Incyte And Two Other Stocks That May Be Priced Below Their Estimated Value - Yahoo Finance
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Stifel Upgrades Incyte (INCY) Rating and Raises Price Target | I - GuruFocus
Incyte (INCY) Surges on Promising Blood Disorder Treatment Results - GuruFocus
Alopecia Areata Market Expected to Experience Major Growth - openPR.com
QGEN Stock Rises in After Market Following Partnership With Incyte - Yahoo Finance
Incyte stock rating reiterated by Oppenheimer on promising cancer drug data - Investing.com Canada
Jefferies raises Incyte stock price target on promising drug data By Investing.com - Investing.com Canada
Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses - Benzinga
Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms - Yahoo Finance
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Jefferies raises Incyte stock price target on promising drug data - Investing.com
Incyte (INCY) Receives Upgrade Amid Promising Drug Data | INCY Stock News - GuruFocus
Incyte stock rating upgraded by Stifel on promising blood disorder drug - Investing.com
Transcript : Incyte CorporationShareholder/Analyst Call - MarketScreener
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025 - BioSpace
Incyte (INCY) Reports Promising Results for Novel Antibody in My - GuruFocus
Incyte (INCY) Receives Upgrade to Buy with $107 Price Target | INCY Stock News - GuruFocus
Incyte (INCY) Reports Promising Results for Novel Antibody in Myeloproliferative Neoplasms | INCY Stock News - GuruFocus
QIAGEN And Incyte Partner To Create New Test For Rare Blood Cancers - Nasdaq
Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches - Insider Monkey
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Quantisnow
Positive Late-Breaking Data for Incyte's First-in-Class mutCALR- - GuruFocus
Incyte’s SWOT analysis: stock faces patent cliff as pipeline progress mixed - Investing.com
Specialised Therapeutics announces expanded partnership with Incyte - Yahoo Finance
Specialised Therapeutics Expands Partnership with Incyte to Incl - GuruFocus
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet - BioSpace
Incyte (INCY) Reports Promising Results from Phase 3 Retifanlimab Trial | INCY Stock News - GuruFocus
Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with - GuruFocus
) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet - Business Wire
Specialised Therapeutics expands oncology portfolio with Incyte deal - Investing.com
Incyte (INCY) Expands Partnership with Specialised Therapeutics in Asia-Pacific | INCY Stock News - GuruFocus
Incyte Doubles Down in Asia-Pacific: New Partnership Brings Breakthrough Cancer Treatments to High-Need Markets - Stock Titan
Incyte Corporation (INCY) Announces Amendments to Stock Incentiv - GuruFocus
Incyte stockholders endorse plan amendments and board members By Investing.com - Investing.com Canada
Incyte stockholders endorse plan amendments and board members - Investing.com
Incyte stock holds steady as UBS maintains neutral rating - Investing.com
Incyte to Showcase Groundbreaking Hematology/Oncology Data at EHA 2025 - MSN
Incyte at Goldman Sachs Conference: Growth Beyond Jakafi - Investing.com
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo
Alnylam, Incyte and GSK led biopharma gains amid earnings volatility - BioWorld MedTech
2.10%
1.57%
자본화:
|
볼륨(24시간):